Related Experiment Video
Updated: Jun 8, 2026
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
EGF receptor in lung cancer: a successful story of targeted therapy
Gelenis Domingo1, Cesar A Perez, Michel Velez
1Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, 1475 NW 12th Avenue, D8-4, Miami, FL 33136, USA.
Abstract:
Lung cancer research has incorporated molecular medicine into the management of this disease during the last 5 years. Several novel tumorigenesis pathways associated with lung cancer development and proliferation have been discovered and further developed as targets. The idea behind this is to deliver individualized therapy for each patient based on his/her tumor phenotype, which may involve the overexpression or lack of certain proteins, receptors, mutations and other factors. To date, many of these characteristics have been shown to have a potential role as prognostic or predictive biomarkers, with most of the available data being obtained from retrospective analyses, various laboratory platforms, and data sets used for comparison. However, well-designed prospective randomized clinical trials are underway to validate the significance and future role of these novel biomarkers, allowing us to sort out the best personalized management for an individual with lung cancer diagnosis. Nevertheless, one of these features, the EGF receptor (EGFR) gene mutation, has emerged as a prognostic and strongly predictive biomarker when EGFR inhibition is used as a therapy for tumors that harbor the mutation. Our article displays the most recently developed data related to this biomarker and what have we learned based on the analyses of clinical trials that have studied different agents in the clinical arena.
Insights
Molecular medicine advances lung cancer treatment by targeting tumor characteristics. Epidermal growth factor receptor (EGFR) gene mutations are key predictive biomarkers for targeted therapies in lung cancer patients.
Area of Science:
- Oncology
- Molecular Medicine
- Genetics
Background:
- Lung cancer management has increasingly integrated molecular medicine over the past five years.
- Novel tumorigenesis pathways driving lung cancer development and proliferation are being identified as therapeutic targets.
- Personalized therapy aims to tailor treatments based on individual tumor phenotypes, including protein expression, receptor status, and mutations.
Purpose of the Study:
- To review recent data on the Epidermal Growth Factor Receptor (EGFR) gene mutation as a biomarker in lung cancer.
- To analyze findings from clinical trials investigating EGFR-targeted therapies.
- To highlight the role of EGFR mutations in personalized lung cancer management.
Main Methods:
- Review of recently developed data concerning EGFR gene mutations.
- Analysis of clinical trial data evaluating different therapeutic agents targeting EGFR.
- Examination of retrospective analyses and laboratory platform data.
Main Results:
- The Epidermal Growth Factor Receptor (EGFR) gene mutation has been established as a significant prognostic and predictive biomarker.
- EGFR-targeted therapies demonstrate efficacy in tumors harboring specific EGFR mutations.
- Ongoing prospective randomized clinical trials are crucial for validating novel biomarkers and refining personalized treatment strategies.
Conclusions:
- EGFR gene mutation status is a critical factor in selecting targeted therapies for lung cancer.
- Personalized medicine approaches, guided by molecular biomarkers, are transforming lung cancer care.
- Continued research and clinical trials are essential for optimizing lung cancer treatment strategies.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...